Analysts See $-0.06 EPS for Protalix BioTherapeutics, Inc. (PLX)

February 24, 2018 - By Hazel Jackson

 Analysts See $ 0.06 EPS for Protalix BioTherapeutics, Inc. (PLX)

Analysts expect Protalix BioTherapeutics, Inc. (NYSEAMERICAN:PLX) to report $-0.06 EPS on March, 15.After having $-0.09 EPS previously, Protalix BioTherapeutics, Inc.’s analysts see -33.33 % EPS growth. The stock increased 0.01% or $0.0001 during the last trading session, reaching $0.6701. About 216,873 shares traded. Protalix BioTherapeutics, Inc. (NYSEAMERICAN:PLX) has declined 0.01% since February 24, 2017 and is downtrending. It has underperformed by 16.71% the S&P500.

Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company has market cap of $96.49 million. The firm offers taliglucerase alfa for injection, which is an enzyme replacement therapy for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease. It currently has negative earnings. The Company’s product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials to treat Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that is in phase II clinical trials to treat cystic fibrosis; and OPRX-106, an oral anti TNF product candidate, which is in Phase II clinical trial for the treatment of ulcerative colitis.

More important recent Protalix BioTherapeutics, Inc. (NYSEAMERICAN:PLX) news were published by: which released: “Protalix Bio’s PRX-102 Fast Track’d for Fabry disease; shares up 9% premarket” on January 31, 2018, also published article titled: “Protalix BioTherapeutics, Inc. (PLX) and Lands’ End, Inc. (LE) Activist Update”, published: “Protalix BioTherapeutics: An Update On The Fabry Disease Franchise” on November 23, 2017. More interesting news about Protalix BioTherapeutics, Inc. (NYSEAMERICAN:PLX) was released by: and their article: “Protalix BioTherapeutics Announces Final Dosing of Last Patient in Phase II …” with publication date: February 15, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: